ArticleJournal of thoracic disease2022

Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial.

Yuxiang Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.